| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
|
Cancer Res
|
2006
|
8.21
|
|
2
|
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.
|
J Urol
|
2008
|
5.30
|
|
3
|
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
|
Proc Natl Acad Sci U S A
|
2004
|
5.13
|
|
4
|
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
|
J Clin Oncol
|
2007
|
3.50
|
|
5
|
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
|
Cancer
|
2003
|
3.33
|
|
6
|
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
|
Clin Cancer Res
|
2007
|
3.23
|
|
7
|
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.
|
Cancer
|
2006
|
3.08
|
|
8
|
Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
|
Clin Cancer Res
|
2007
|
2.26
|
|
9
|
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.
|
Proc Natl Acad Sci U S A
|
2006
|
2.24
|
|
10
|
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
|
Cancer Res
|
2007
|
2.19
|
|
11
|
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
|
Cancer
|
2007
|
2.00
|
|
12
|
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma.
|
Cancer
|
2009
|
2.00
|
|
13
|
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
|
Clin Cancer Res
|
2008
|
1.97
|
|
14
|
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.
|
Clin Lung Cancer
|
2012
|
1.93
|
|
15
|
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
|
J Urol
|
2008
|
1.83
|
|
16
|
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
|
J Urol
|
2005
|
1.80
|
|
17
|
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.
|
Blood
|
2009
|
1.74
|
|
18
|
Augmentation of T cell levels and responses induced by androgen deprivation.
|
J Immunol
|
2004
|
1.71
|
|
19
|
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
|
Cancer
|
2005
|
1.71
|
|
20
|
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
|
Clin Cancer Res
|
2007
|
1.59
|
|
21
|
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
|
BJU Int
|
2013
|
1.59
|
|
22
|
T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
|
Clin Cancer Res
|
2008
|
1.58
|
|
23
|
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.
|
Cancer
|
2008
|
1.45
|
|
24
|
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
|
Cancer
|
2005
|
1.43
|
|
25
|
Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
|
J Urol
|
2005
|
1.42
|
|
26
|
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
|
J Urol
|
2005
|
1.42
|
|
27
|
Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
|
Cancer
|
2006
|
1.40
|
|
28
|
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.
|
Clin Cancer Res
|
2011
|
1.38
|
|
29
|
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.
|
J Urol
|
2005
|
1.38
|
|
30
|
Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
|
Clin Cancer Res
|
2007
|
1.30
|
|
31
|
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
|
J Urol
|
2005
|
1.24
|
|
32
|
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.
|
Cancer Res
|
2008
|
1.21
|
|
33
|
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
|
Cancer
|
2006
|
1.20
|
|
34
|
Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers.
|
Cancer
|
2008
|
1.16
|
|
35
|
Costimulation, coinhibition and cancer.
|
Curr Cancer Drug Targets
|
2007
|
1.15
|
|
36
|
Second primary malignancies associated with renal cell carcinoma histological subtypes.
|
J Urol
|
2006
|
1.15
|
|
37
|
Tissue microarrays: one size does not fit all.
|
Diagn Pathol
|
2010
|
1.10
|
|
38
|
TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.
|
J Immunol
|
2009
|
1.08
|
|
39
|
Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.
|
Cancer
|
2007
|
1.07
|
|
40
|
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
|
Clin Cancer Res
|
2007
|
1.07
|
|
41
|
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
|
J Thorac Oncol
|
2014
|
1.07
|
|
42
|
Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation.
|
Urology
|
2008
|
1.05
|
|
43
|
Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas.
|
Cancer
|
2008
|
1.05
|
|
44
|
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
|
Urology
|
2005
|
1.03
|
|
45
|
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.
|
Front Oncol
|
2013
|
1.01
|
|
46
|
Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.
|
Cancer
|
2005
|
1.00
|
|
47
|
Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma.
|
J Immunol
|
2008
|
1.00
|
|
48
|
Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion.
|
Am J Surg Pathol
|
2007
|
0.99
|
|
49
|
B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence.
|
J Urol
|
2008
|
0.98
|
|
50
|
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
|
Urol Oncol
|
2006
|
0.97
|
|
51
|
Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.
|
Oncoimmunology
|
2013
|
0.97
|
|
52
|
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
|
Clin Cancer Res
|
2009
|
0.96
|
|
53
|
Immunotherapy for urological malignancies.
|
J Urol
|
2004
|
0.96
|
|
54
|
Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment.
|
J Urol
|
2012
|
0.95
|
|
55
|
The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.
|
Cancer
|
2006
|
0.94
|
|
56
|
Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma.
|
Urology
|
2008
|
0.93
|
|
57
|
Significance of B7-H1 overexpression in kidney cancer.
|
Clin Genitourin Cancer
|
2006
|
0.93
|
|
58
|
B7-h1 expressed by activated CD8 T cells is essential for their survival.
|
J Immunol
|
2011
|
0.93
|
|
59
|
Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.92
|
|
60
|
The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.
|
J Urol
|
2006
|
0.92
|
|
61
|
Early effects of pharmacological androgen deprivation in human prostate cancer.
|
BJU Int
|
2007
|
0.92
|
|
62
|
Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma.
|
Hum Pathol
|
2008
|
0.91
|
|
63
|
pT2 classification for renal cell carcinoma. Can its accuracy be improved?
|
J Urol
|
2005
|
0.90
|
|
64
|
Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.
|
Cancer Immunol Res
|
2013
|
0.89
|
|
65
|
B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim.
|
Oncoimmunology
|
2012
|
0.88
|
|
66
|
Immunotherapy for prostate cancer.
|
Curr Pharm Des
|
2006
|
0.87
|
|
67
|
Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
|
J Urol
|
2006
|
0.86
|
|
68
|
Prostate cancer: advances in immunotherapy.
|
BioDrugs
|
2003
|
0.85
|
|
69
|
Prostate cancer immunology: biology, therapeutics, and challenges.
|
J Clin Oncol
|
2005
|
0.85
|
|
70
|
Potential role of genetic markers in the management of kidney cancer.
|
Eur Urol
|
2012
|
0.84
|
|
71
|
Soluble B7-H1: differences in production between dendritic cells and T cells.
|
Immunol Lett
|
2011
|
0.83
|
|
72
|
B7-H1 expression in vestibular schwannomas.
|
Otol Neurotol
|
2010
|
0.83
|
|
73
|
Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
|
Cancer
|
2008
|
0.82
|
|
74
|
T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.
|
Urology
|
2009
|
0.81
|
|
75
|
Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma.
|
J Urol
|
2006
|
0.81
|
|
76
|
B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation.
|
Cancer Immunol Immunother
|
2014
|
0.80
|
|
77
|
Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome.
|
Am J Hematol
|
2011
|
0.80
|
|
78
|
Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy.
|
Urology
|
2006
|
0.80
|
|
79
|
Immunotherapy in prostate cancer.
|
Curr Urol Rep
|
2015
|
0.78
|
|
80
|
Inhibitors of B7-CD28 costimulation in urologic malignancies.
|
Immunotherapy
|
2009
|
0.77
|
|
81
|
Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564.
|
J Urol
|
2009
|
0.75
|